Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Prospective, Randomized, Open-Labeled, Active-Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine, GC FLU, in Adults Aged 20 to 50

NCT03718468 is registered in ClinicalTrials.gov with Medigen Vaccine Biologics Corp. as lead sponsor.

NCT NCT03718468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03718468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Prospective, Randomized, Open-Labeled, Active-Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine, GC FLU, in Adults Aged 20 to 50
Lead sponsor
Medigen Vaccine Biologics Corp.
Phase
Phase 3
Overall status
Completed
Start date
October 30, 2018
Completion date
July 3, 2019
Enrollment
842 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

influenza